Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.05.18	Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto® (GlobeNewswire)
24.05.18	Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases (GlobeNewswire)
18.05.18	Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention (GlobeNewswire)
17.05.18	Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer (GlobeNewswire)
16.05.18	At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth (GlobeNewswire)
16.05.18	Novartis kündigt Veränderungen in der Geschäftsleitung an (GlobeNewswire)
16.05.18	Novartis announces changes to the Executive Committee (GlobeNewswire)
15.05.18	Novartis successfully completes acquisition of AveXis, Inc. (GlobeNewswire)
15.05.18	Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*) (GlobeNewswire)
15.05.18	Novartis completes tender offer for all outstanding shares of AveXis, Inc. (GlobeNewswire)
12.05.18	Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis (GlobeNewswire)
07.05.18	Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally (GlobeNewswire)
02.05.18	Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab (GlobeNewswire)
01.05.18	Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma (GlobeNewswire)
01.05.18	Novartis provides update on proposed acquisition of AveXis (GlobeNewswire)
30.04.18	Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma (GlobeNewswire)
30.04.18	New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval (GlobeNewswire)
25.04.18	Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home (GlobeNewswire)
20.04.18	New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients (GlobeNewswire)
19.04.18	Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer (GlobeNewswire)
19.04.18	Novartis verzeichnet ein starkes erstes Quartal und ergreift Schritte, um ein stärker fokussiertes Arzneimittelunternehmen zu werden (GlobeNewswire)
19.04.18	Novartis delivered a strong first quarter and acted to become a more focused medicines company (GlobeNewswire)
18.04.18	Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders (GlobeNewswire)
17.04.18	Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures (GlobeNewswire)
17.04.18	Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials (GlobeNewswire)
17.04.18	Novartis bekräftigt Engagement zur Eliminierung von Malaria und investiert USD 100 Millionen in die Erforschung und Entwicklung der nächsten Generation von Malariamedikamenten (GlobeNewswire)
17.04.18	Novartis tender offer for AveXis commences (GlobeNewswire)
16.04.18	Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes (GlobeNewswire)
09.04.18	Novartis schliesst Vereinbarung zum Erwerb von AveXis Inc. für USD 8,7 Mrd ab, um Therapie der SMA zu transformieren und Position als führendes Gentherapie-und Neuroscience-Unternehmen auszubauen (GlobeNewswire)
09.04.18	Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader (GlobeNewswire)
04.04.18	Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril (GlobeNewswire)
28.03.18	Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO (GlobeNewswire)
27.03.18	Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities (GlobeNewswire)
27.03.18	Novartis verkauft Beteiligung an Consumer-Healthcare-Joint-Venture für USD 13 Milliarden an GSK, um sich auf strategische Prioritäten zu konzentrieren (GlobeNewswire)
23.03.18	Sandoz receives positive CHMP opinion for proposed biosimilar infliximab (GlobeNewswire)
23.03.18	Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS (GlobeNewswire)
22.03.18	Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia (GlobeNewswire)
20.03.18	Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies (GlobeNewswire)
12.03.18	Novartis kündigt Veränderungen in der Geschäftsleitung zur Unterstützung strategischer Prioritäten an (GlobeNewswire)
12.03.18	Novartis announces changes to the Executive Committee to support strategic priorities (GlobeNewswire)
07.03.18	Novartis expands alliance with Science 37 to advance virtual clinical trials program (GlobeNewswire)
06.03.18	Novartis' Xolair® recommended in new global chronic urticaria guideline (GlobeNewswire)
02.03.18	Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting (GlobeNewswire)
02.03.18	Novartis Aktionäre genehmigen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats (GlobeNewswire)
01.03.18	Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis (GlobeNewswire)
22.02.18	Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation (GlobeNewswire)
16.02.18	Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis (GlobeNewswire)
16.02.18	Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis (GlobeNewswire)
14.02.18	Novartis forms alliance to develop medicines for treating infectious diarrheal disease (GlobeNewswire)
13.02.18	Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		Börse New York in Grün: So steht der NASDAQ 100 aktuell
20.12.24		SPI-Handel aktuell: SPI zum Handelsende leichter
20.12.24		Schwacher Handel: SMI schliesst mit Verlusten
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter
20.12.24		Handel in Europa: STOXX 50 schliesst im Minus

20.12.24

Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone

20.12.24

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

20.12.24

Dow Jones aktuell: Dow Jones notiert am Mittag im Plus

20.12.24

Börse New York in Grün: So steht der NASDAQ 100 aktuell

20.12.24

SPI-Handel aktuell: SPI zum Handelsende leichter

20.12.24

Schwacher Handel: SMI schliesst mit Verlusten